Here is the design of a clinical trial:

Official Title: Efficacy of Extended Infusion of β-lactam Antibiotics for the Treatment of Febrile Neutropenia in Haematologic Patients: a Randomised, Multicentre, Open-label, Superiority Clinical Trial (BEATLE)

Included conditions:
- Febrile Neutropenia

Study Armgroups:
- {'label': 'Extended infusion', 'type': 'EXPERIMENTAL', 'description': 'Piperacillin-tazobactam, cefepime or meropenem will be administered in half time of the dosing interval', 'interventionNames': ['Drug: Piperacillin-Tazobactam 4 g-0.5 g', 'Drug: Cefepime 2000 mg', 'Drug: Meropenem 1000 mg']}
- {'label': 'Intermittent infusion', 'type': 'ACTIVE_COMPARATOR', 'description': 'Piperacillin-tazobactam, cefepime or meropenem will be administered in 30 minutes', 'interventionNames': ['Drug: Piperacillin-Tazobactam 4 g-0.5 g', 'Drug: Cefepime 2000 mg', 'Drug: Meropenem 1000 mg']}

Interventions:
- {'type': 'DRUG', 'name': 'Piperacillin-Tazobactam 4 g-0.5 g', 'description': 'Patients with FN who empirical treatment with piperacillin-tazobactam 4g/6h', 'armGroupLabels': ['Extended infusion', 'Intermittent infusion']}
- {'type': 'DRUG', 'name': 'Cefepime 2000 mg', 'description': 'Patients with FN who required empirical treatment with cefepime 2g/8h', 'armGroupLabels': ['Extended infusion', 'Intermittent infusion']}
- {'type': 'DRUG', 'name': 'Meropenem 1000 mg', 'description': 'Patients with FN who required empirical treatment with meropenem 1g/8h', 'armGroupLabels': ['Extended infusion', 'Intermittent infusion']}

Primary Outcomes:
- {'measure': 'Clinical efficacy of extended infusion: Number of patients with defervescence', 'description': 'Number of patients with defervescence (\\<37.5 ºC, for 24 hours) without modifying the antibiotic treatment', 'timeFrame': '5 days'}

Please estimate the sample size based on the assumption: 
An alpha risk of 0.05 and a beta risk of 0.2 in a bilateral contrast are assumed, with the sample size allowing up to 20% losses to follow-up.
Sample size
        The sample size calculation is based on determining whether the administration of BLA by EI (study group) will be clinically more effective than the administration of BLA by II (control group), for the treatment of FN in haematological patients. Previous data suggest that the clinical efficacy rate in the control group is expected to be 0.45 [20, 21]. A relevant clinical efficacy rate in the study group is expected to be 0.70. Each therapy group will required 75 participants (total of 150) to detect statistically significant differences in clinical efficacy. An alpha risk of 0.05 and a beta risk of 0.2 in a bilateral contrast are assumed, and the sample size allows up to 20% losses to follow-up.
        
          Interim analysis
          An interim analysis will be carried out once 50% of the cases of each arm are recruited. This analysis will evaluate if the estimated sample size is adequate. The results will be issued by an independent committee of experts not participating in this study.